Skip to the page

Data / Drug companies / Unichem Pharmaceuticals (USA), Inc.

Unichem Pharmaceuticals (USA), Inc.: 178 products in the FDA NDC directory, labeler code 29300

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Unichem Pharmaceuticals (USA), Inc. (labeler code 29300) lists 178 products in the FDA National Drug Code Directory, covering 56 finished drugs by generic name. By type: 177 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.

The request: Watch Unichem Pharmaceuticals (USA), Inc. (FDA labeler code 29300): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
29300
Products in commercial distribution
178
Packages
487
Finished drugs by generic name
56
Prescription products
177
Over the counter products
1
Controlled substance products
Schedule IV 7, Schedule V 12
Flagged as original packager
164 of 164 products that carry the flag
Started marketing in the last 12 months
12
Earliest marketing start
March 7, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)178100%

Products by type

TypeProductsShare
Prescription drugs17799.4%
Over the counter drugs10.6%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet7843.8%
Tablet, film coated5128.7%
Capsule2011.2%
Tablet, extended release126.7%
Tablet, film coated, extended release52.8%
Tablet, orally disintegrating42.2%
Capsule, extended release31.7%
Tablet, delayed release31.7%
Tablet, chewable21.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Alprazolam29300-363TabletGeneric drugs (ANDA)November 2, 2026
Alprazolam29300-362TabletGeneric drugs (ANDA)November 2, 2026
Alprazolam29300-361TabletGeneric drugs (ANDA)November 2, 2026
Alprazolam29300-360TabletGeneric drugs (ANDA)November 2, 2026
Pregabalin29300-446CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-445CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-444CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-443CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-442CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-441CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-440CapsuleGeneric drugs (ANDA)August 3, 2026
Pregabalin29300-439CapsuleGeneric drugs (ANDA)August 3, 2026
Hydrochlorothiazide29300-485TabletGeneric drugs (ANDA)April 3, 2025
Lacosamide29300-367Tablet, film coatedGeneric drugs (ANDA)December 1, 2024
Lacosamide29300-366Tablet, film coatedGeneric drugs (ANDA)December 1, 2024
Lacosamide29300-365Tablet, film coatedGeneric drugs (ANDA)December 1, 2024
Lacosamide29300-364Tablet, film coatedGeneric drugs (ANDA)December 1, 2024
Guanfacine29300-463Tablet, extended releaseGeneric drugs (ANDA)November 19, 2024
Guanfacine29300-462Tablet, extended releaseGeneric drugs (ANDA)November 19, 2024
Guanfacine29300-461Tablet, extended releaseGeneric drugs (ANDA)November 19, 2024
Guanfacine29300-460Tablet, extended releaseGeneric drugs (ANDA)November 19, 2024
Tolterodine tartrate29300-307Capsule, extended releaseGeneric drugs (ANDA)October 1, 2024
Tolterodine tartrate29300-306Capsule, extended releaseGeneric drugs (ANDA)October 1, 2024
Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride29300-313Tablet, film coated, extended releaseGeneric drugs (ANDA)September 10, 2024
Doxazosin Mesylate29300-354TabletGeneric drugs (ANDA)January 10, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.